AbbVie

Open: 165.85 Close: 163.91 Change: -1.94

We programmed an AI to read Internet. This is what it found out about AbbVie Stock.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, new, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility. The project is expected to create more than 100 new jobs and bolster Abbvies global biologics manufacturing capacity. The company scored a 84 in the Healthcare sector, ranking it higher than 84% of stocks.

Today's News

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility. The project is expected to create more than 100 new jobs and bolster Abbvies global biologics manufacturing capacity. The new investment is pegged to add 24,000 liters. AbbVie will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024, before the market opens. The company is expected to post earnings of $2.76 per share. SAP Global Trade Services – Associate Business Systems Consultant at abbvie.com. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVies global network. Market Access Insights (MABI) organization within MABI plays an instrumental role in shaping market access strategies for all of AbbVies domestic brands. MABI provides insights that directly impact patient and physician access to the companys brands. AbbVie Inc (ABBV) stock has fallen -0.47% while the S&P 500 has risen 0.3% as of 12:10 PM on Thursday, Jan 25. Abbvie Inc scored a 84 in the Healthcare sector, ranking it higher than 84% of stocks in that sector. Abvie is a pharmaceutical firm with a strong exposure to immunology. AbbVie has developed a strong, diversified portfolio that is heavily protected with long-dated patents. The company has had to depend on acquisitions to boost its late-stage pipeline. There are 4495 funds or institutions reporting positions in AbbVie. This is an increaseof92owner(s) or 2.09% in the last quarter. The projected annual revenue for Abbvieis 55,243MM, an increase of 0.19%. The annual non-GAAP EPS is 11.73%. AbbVie is committed to operating with integrity, driving innovation, transforming lives, serving our community, and embracing diversity and inclusion. The revenue for ABBV-668 is expected to reach an annual total of $23 mn by 2036 in the US based off GlobalDatas Expiry Model.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, new, expect, company, MABI, annual, project, and the most common words in the summary are: abbvie, stock, job, market, option, get, direction, . One of the sentences in the summary was: The project is expected to create more than 100 new jobs and bolster Abbvies global biologics manufacturing capacity. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #job #market #option #get #direction.